News
-
-
-
-
PRESS RELEASE
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
BioNxt Solutions Inc. reports progress in toxicity and PK studies, advancing towards human comparative bioavailability studies. Development includes technology transfer, upscaling, & clinical sample prep for bioequivalence study -
-
PRESS RELEASE
BioNxt Reports Successful Results From ODF Cladribine PK Study
BioNxt Solutions Inc. announces successful completion of comparative pharmacokinetic study for its oral dissolvable film Cladribine product for Multiple Sclerosis treatment, demonstrating rapid absorption similar to reference drug -
-
-
-
-
Arras Minerals Closes C$5.2 Million Non-Brokered Financing
-
Aston Bay Holdings Closes $2,137,860 Second Tranche of Non-Brokered Private Placement for $3,517,860 Total to Date
-
Apex Critical Metals Corp. Signs Earn-In Agreement with Discovery Lithium & DG Resource Management
-
Discovery Lithium Announces Earn-In Option on Quebec Property Portfolio
-
Zimtu Capital Announces Agreement with Apex Critical Metals
-
Patrimonium Swiss Real Estate Fund: stable results in a difficult environment
-
Molten Ventures Plc: HOL-Holding(s) in Company
-
Eighteenth Annual General Meeting of Delticom AG
-
Annual General Meeting of CANCOM SE elects Supervisory Board and approves dividend of € 1.00
-
PNE AG successfully sells its US division to Lotus Infrastructure Partners
-
Shareholders’ Meeting and Board of Directors’ meeting on June 6, 2024
-
Disclosure of voting rights - 06.06.2024
-
Eurazeo announces the signing by Grape Hospitality of an exclusivity agreement for the sale of 23 hotels
-
Safran: Update on proposed acquisition of Collins Aerospace’s actuation and flight control business
-
Aéroports de Paris SA - Voting rights as of 31 May 2024